| Name | Title | Contact Details |
|---|
NEOMED is a Woodstock, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sarah Bush Lincoln Health Center is a 129-bed, not-for-profit, regional hospital centrally located in East Central Illinois Coles County, and is the recipient of the 2011 Illinois Performance Excellence Gold Award for Achievement of Excellence, the highest performance honors in the state. Sarah Bush Lincoln is accredited by The Joint Commission, the nations oldest and largest standards-setting and accrediting body in healthcare. The Health Center provides a full range of acute care services to residents of Coles County and the surrounding eight counties. Home health services extend to the surroundings 19 counties in East Central and Southern Illinois. Active and consulting medical staffs include approximately 175 providers representing 28 specialties. Some of the services provided by the Health Center include: a Regional Cancer Center, a Heart Center with Cardiac Catheterization and Rehabilitation in partnership with Prairie Heart Institute of Illinois, a Surgery Center, Women & Childrens Services, a Level II Perinatal Unit, Medical-Surgical units, Behavioral Health Services, Close Observation Unit, a Sleep Disorders Center, Diagnostic Imaging Services, and Laboratory. Outreach services include a durable medical company (Lincolnland Home Medical Equipment), a Reference Laboratory, Peace Meal, Lincolnland Home Health and Hospice, Lifeline, and Lincolnland Homemakers. Sarah Bush Lincoln has 14 extended campus primary care locations and three walk-in clinics. Employing about 2,350 area residents, the Health Center promotes a culture of excellence through continuing personal and professional growth.
Supplements made to the highest standards, and formulated to make a real difference in your life. Find your next game changer from the supplement brand you can trust.
Crux Biomedical is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."